Persistent Strengthens Life Sciences AI Through Databricks
SANTA CLARA, Calif. and PUNE, India , May 7, 2026 Persistent Systems announced it has achieved the Databricks Brickbuilder...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SANTA CLARA, Calif. and PUNE, India , May 7, 2026 Persistent Systems announced it has achieved the Databricks Brickbuilder...
Stockholm, Sweden | April 30, 2026 Moleculent has announced the successful closing of a $20 million financing round, aimed...
CAMBRIDGE, UK, April 24, 2026 Amphista Therapeutics has unveiled new preclinical data demonstrating the therapeutic potential of its SMARCA2...
Ingelheim, Germany, April 20, 2026 Boehringer Ingelheim has announced a major strategic expansion of its computational innovation capabilities with...
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
BOSTON, Massachusetts, United States, April 7, 2026 Alloy Therapeutics Inc. announced a multi-target collaboration and license agreement with Biogen...
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to...
CAMBRIDGE, UK, March 31, 2026 Semarion, a University of Cambridge spin-out company, has announced the successful raise of $3.8...
CAMBRIDGE, MASSACHUSETTS, March 24, 2026 Quotient Therapeutics has announced a multi-year research collaboration with Merck & Co. to discover...
SANTA CRUZ, Calif., March 16, 2026 Unnatural Products has announced the successful closing of a $45 million Series B...
